- Home
- ENLV vs ALEC Comparison
ENLV vs ALEC Comparison
Compare ENLV & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ENLV | ALEC |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.3M | 204.1M |
| IPO Year | 2014 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ENLV | ALEC |
|---|---|---|
| Price | $1.14 | $2.55 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 7 |
| Target Price | ★ $13.00 | $3.33 |
| AVG Volume (30 Days) | 336.3K | ★ 793.0K |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $21,045,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.66 | $0.87 |
| 52 Week High | $2.10 | $3.40 |
Technical Indicators
Market Signals| Indicator | ENLV | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 57.00 | 81.81 |
| Support Level | $1.00 | $2.30 |
| Resistance Level | $1.23 | $3.34 |
| Average True Range (ATR) | 0.07 | 0.16 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 56.00 | 96.60 |
Price Performance
Historical ComparisonAbout ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.